No abstract available.
Inflammatory Bowel Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Inflammatory Bowel Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Intestinal Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Humans ; Inflammatory Bowel Diseases* ; Korea* ; Leukocyte L1 Antigen Complex*

No abstract available.
Colitis, Ulcerative* ; Humans ; Leukocyte L1 Antigen Complex* ; Ulcer*

No abstract available.
Humans ; Inflammatory Bowel Diseases* ; Leukocyte L1 Antigen Complex*

BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored. RESULTS: Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups. CONCLUSIONS: Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.
Adult ; Asian Continental Ancestry Group* ; Crohn Disease* ; Humans ; Leukocyte L1 Antigen Complex ; Pharmacokinetics

No abstract available.
Constipation/*diagnosis ; Female ; Hirschsprung Disease/*diagnosis ; Humans ; Leukocyte L1 Antigen Complex/*analysis ; Male

<b>OBJECTIVESb>To study the essence of N-terminal amino acid sequence of 12 000-protein in gingival crevicular fluid (GCF).

<b>METHODSb>GCF samples from patients with RPP and AP were collected. 12 000-protein was separated by SDS-PAGE and transformed to PVDF by electronic transformation. The aim band was cut to be analyzed in 491 Protein Sequencer.

<b>RESULTSb>The first ten of N-terminal amino acid sequence of 12 000-protein in GCF was Met, Leu, Thr, Glu, Leu, Glu, Lys, Ala, Leu, Asn. Through checking up in MS-Edman, the sequence was similar to "Ca binding protein, MRP8" which is the light subunit of Calprotectin.

<b>CONCLUSIONSb>Calprotectin is a major protein in granulocytes and monocytes, and is related to many inflammatory diseases, maybe served as a effective marker for evaluating the inflammation of periodontium.

BACKGROUND/AIMS: Both fecal immunochemical test (FIT) and fecal calprotectin (Fcal) results are useful biomarkers for ulcerative colitis (UC). However, the situations in which each marker should be used are largely unknown. METHODS: A total of 110 colonoscopy intervals of UC patients were assessed, and correlations between changes in colonoscopic findings and changes in the two aforementioned fecal markers were examined. RESULTS: Among patients with mucosal healing (MH) and negative FIT or Fcal results at the initial colonoscopy, FIT and Fcal findings exhibited accuracies of 93% (38/41) and 79% (26/33), respectively, for predicting the results of the subsequent examination. Among the 24 patients who showed endoscopic activity at the precedent colonoscopy and MH at the subsequent examination, positive-to-negative conversion of FIT and Fcal findings at the subsequent examination was observed in 92% (12/13) and 62% (8/13) of patients, respectively. Among the 43 patients who showed endoscopic activity at both the precedent and subsequent examinations, Fcal findings reflected the change in endoscopic activity better than FIT results (r=0.59, p<0.0001 vs r=0.30, p=0.054). CONCLUSIONS: The FIT is useful for confirming MH and the occurrence of relapse. In contrast, Fcal is useful for monitoring the mucosal status of patients with active inflammation.
Biomarkers ; Colitis ; Colitis, Ulcerative* ; Colonoscopy ; Humans ; Inflammation ; Leukocyte L1 Antigen Complex* ; Recurrence ; Ulcer*